Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tipifarnib - Kura Oncology

Drug Profile

Tipifarnib - Kura Oncology

Alternative Names: NSC-702818; R-115777; Zarnestra

Latest Information Update: 22 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen L.P.; Janssen-Cilag; Johnson & Johnson
  • Developer Emory University; H. Lee Moffitt Cancer Center and Research Institute; Janssen-Cilag; Johnson & Johnson; Kura Oncology; National Cancer Institute (USA); Samsung Medical Center; Spanish Lung Cancer Group; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Quinolones; Small molecules
  • Mechanism of Action CXCL12 protein inhibitors; Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Pancreatic cancer
  • Phase II Chronic myelomonocytic leukaemia; Head and neck cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Peripheral T-cell lymphoma; Thyroid cancer; Urogenital cancer
  • Phase I/II Multiple myeloma
  • Preclinical Cutaneous T-cell lymphoma
  • Discontinued Breast cancer; Glioblastoma

Most Recent Events

  • 18 Jan 2019 Phase III development is ongoing in USA
  • 02 Dec 2018 Updated efficacy and adverse events data from a phase II trial in Peripheral T-cell lymphoma (Second-line therapy or greater) presented at the 60th Annual Meeting of the American Society of Haematology (ASH-2018)
  • 28 Nov 2018 Kura Oncology has patent protection for tipifarnib for treatment of Angioimmunoblastic T-cell lymphoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top